September 18, 2020 at 11:00 AM EST

Bloomberg Intelligence and inThought host a call with Spinal Muscular Atrophy experts for an in-depth review of the spinal muscular atrophy (SMA) treatment landscape, which now includes approved drugs from Biogen, Novartis and Roche.


  • Adrian Krainer, PhD of Cold Spring Harbor Laboratory
  • Thomas O. Crawford, M.D. is Director of the MDA clinic for Neuromuscular Disorders at Johns Hopkins


  • Marc Engelsgjerd, MD Senior Analyst, Bloomberg Intelligence
  • Sam Fazeli, PhD Head of EMEA Research, Bloomberg Intelligence
  • Michelle Rivera, PhD Senior Analyst, inThought Research